Ganirelix Taro 0.25 mg/0.5 ml

/ Taro International Ltd

This medical product should be injected subcutaneously once daily, starting on day 5 or day 6 of FSH administration or on day 5 or day 6 following the administration of corifollitropin alfa. The starting day is depending on the ovarian response, i.e. the number and size of growing follicles and/or the amount of circulating oestradiol. The start may be delayed in absence of follicular growth, although clinical experience is based on starting on day 5 or day 6 of stimulation.
This medical product and FSH should be administered approximately at the same time. However, the preparations should not be mixed and different injection sites are to be used.
Please refer to the license holder for further details.

Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian stimulation in the setting of fertility treatments.

* Hypersensitivity to the active substance or to any of the excipients
* Hypersensitivity to gonadotrophin-releasing homrone (GnRH) or any other GnRH analogue
* Moderate or severe impairment of renal or hepatic function
* Pregnancy or lactation.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.